Article
The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting.
Pharmacogenetics and genomics - 1 Mar 2012
Harmsze Ankie M, van Werkum Jochem W, Hackeng Christian M, Ruven Hendrik J T, Kelder Johannes C, Bouman Heleen J, Breet Nicoline J, Ten Berg Jurriën M, Klungel Olaf H, de Boer Anthonius, Deneer Vera H M
Abstract excerpt
OBJECTIVES: To investigate the impact of genotypes on the basis of the loss-of-function variant CYP2C19*2 and the gain-of-function variant CYP2C19*17 on on-treatment platelet reactivity and on the occurrence of Thrombolysis in Myocardial Infarction (TIMI) major bleedings in 820 clopidogrel-treated patients who underwent elective coronary stenting. METHODS: On-treatment platelet reactivity was quantified using...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
